Anticancer Drugs Oncology Pharmacology Physiotherapy Ruxolitinib


In this article we will discuss about Ruxolitinib (Dosage Overview)

In this article, we will discuss about Ruxolitinib (Dosage Overview). So, let’s get started.

Ruxolitinib is a kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.


• The starting dose of ruxolitinib is 20 mg given orally twice daily for patients with a platelet count greater than 200 X 109/L, and 15 mg twice daily for patients with a platelet count between 100 X 109/L and 200 X 109/L.
• Perform a complete blood count before initiating therapy with Jakafi. Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify dose for thrombocytopenia.
• Increase dose based on response and as recommended to a maximum of 25 mg twice daily. Discontinue after 6 months if no spleen reduction or symptom improvement.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.